Metronidazole resistance as outcome (n = 189) | ||||
---|---|---|---|---|
Univariate analysis | Multivariate analysis | |||
Clinical characteristics | OR (95% CI) | P Value | OR(95% CI) | P Value |
Prolonged hospital stayb (≥ 7 days of hospital admission) | 1.1 (0.5–2.5) | 0.869 | 0.6 (0.2–1.7) | 0.381 |
Age group (< 18 years as reference) | 0.338 | |||
18–60 years | 2.6 (0.7–9.0) | 0.144 | ||
> 60 years | 2.5 (0.6–10.7) | 0.214 | ||
Female (Male as reference) | 0.5 (0.2–1.2) | 0.128 | ||
Organisms (Clostridium species as reference) | 0.876 | |||
Bacteroides fragilis | 0.6 (0.06–5.1) | 0.611 | ||
Bacteroides other than fragilis | 1.2 (0.5–3.0) | 0.662 | ||
Othersa | 1.016 (0.3–3.1) | 0.978 | ||
Diabetes Mellitus | 0.3 (0.06–1.3) | 0.119 | ||
Malignancy/transplant | 5.6 (1.7–17.9) | 0.003 | 6.3(1.7–23.3) | 0.005 |
Dialysis | 4.2(0.2–68.5) | 0.315 | ||
Bacteremia | 2.3 (1.0–5.1) | 0.041 | 2.1 (0.9–4.7) | 0.089 |
Skin and soft tissue infection | 0.6 (0.2–1.3) | 0.181 | ||
Head and neck infections | 0.4 (0.09–2.0) | 0.302 | ||
Intraabdominal infections | 1.1 (0.5–2.4) | 0.739 | ||
Respiratory tract infections | 2.1 (0.4–11.9) | 0.399 | ||
Genitourinary infections | 0.5 (0.1–2.4) | 0.402 | ||
Expired | 2.5 (0.7–9.0) | 0.161 |